Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Immuneering Corporation

< Previous 1 2 3 Next >
News headline image
Immuneering to Present at the ESMO Congress 2026
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the AACR Conference on Pancreatic Cancer, Highlighting Atebimetinib’s Dual Mechanism for Extended Survival
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Participate in Upcoming Investor Conferences
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Comments on Today’s FDA Approval in Second-Line Metastatic Pancreatic Cancer, Reiterates Focus on First-Line Patients
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Second Quarter 2026 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Corporation Announces Grants of Inducement Awards
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Appoints Andrew Gengos as Chief Financial Officer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces First Patient Dosed in Pivotal Phase 3 MAPKeeper 301 Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports 17.3 Months Median Overall Survival in First-Line Metastatic Pancreatic Cancer Patients Treated with Atebimetinib Plus Chemotherapy
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports First Quarter 2026 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present New Survival Data from First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP in an Oral Presentation at the 2026 ASCO Annual Meeting
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Presents Genetic Data at AACR Annual Meeting Demonstrating Mechanism to Improve Durability and Survival, Supporting Use of Atebimetinib in First-Line Pancreatic Cancer and Beyond
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the 25th Annual Needham Virtual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present Molecular Data at 2026 AACR Annual Meeting from Atebimetinib-Treated Patients, Highlighting Mechanism Designed to Improve Durability and Survival
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Leerink Global Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Exceptional 64% Overall Survival At 12 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI)
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
News headline image
Immuneering Announces Extraordinary 86% Overall Survival at 9 Months in First-Line Pancreatic Cancer Patients Treated with Atebimetinib + mGnP
From Immuneering Corporation
Via GlobeNewswire
Tickers IMRX
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.